Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics


Arbutus Biopharma Corporation (ABUS): $3.07

-0.24 (-7.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

ABUS POWR Grades


  • ABUS scores best on the Growth dimension, with a Growth rank ahead of 79.85% of US stocks.
  • ABUS's strongest trending metric is Stability; it's been moving down over the last 157 days.
  • ABUS ranks lowest in Stability; there it ranks in the 6th percentile.

ABUS Stock Summary

  • Of note is the ratio of Arbutus Biopharma Corp's sales and general administrative expense to its total operating expenses; only 8.72% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Arbutus Biopharma Corp is higher than it is for about merely 8.72% of US stocks.
  • With a price/sales ratio of 44.03, Arbutus Biopharma Corp has a higher such ratio than 95.59% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Arbutus Biopharma Corp, a group of peers worth examining would be MGNX, SYRS, LPTX, SQZ, and ZYME.
  • Visit ABUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arbutusbio.com.

ABUS Valuation Summary

  • In comparison to the median Healthcare stock, ABUS's EV/EBIT ratio is 115.7% lower, now standing at -4.6.
  • Over the past 142 months, ABUS's price/earnings ratio has gone up 1.4.
  • ABUS's price/sales ratio has moved up 37.4 over the prior 142 months.

Below are key valuation metrics over time for ABUS.

Stock Date P/S P/B P/E EV/EBIT
ABUS 2021-08-31 40.7 3.4 -4.0 -4.6
ABUS 2021-08-30 40.1 3.3 -4.0 -4.5
ABUS 2021-08-27 39.5 3.3 -3.9 -4.4
ABUS 2021-08-26 38.6 3.2 -3.8 -4.3
ABUS 2021-08-25 38.7 3.2 -3.8 -4.3
ABUS 2021-08-24 38.6 3.2 -3.8 -4.3

ABUS Growth Metrics

    The 5 year price growth rate now stands at -68.97%.
  • The 4 year revenue growth rate now stands at -67.19%.
  • Its 2 year price growth rate is now at -75.59%.
ABUS's revenue has moved up $4,223,000 over the prior 33 months.

The table below shows ABUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 10.168 -62.939 -86.656
2021-06-30 8.351 -59.077 -84.193
2021-03-31 7.536 -53.869 -78.622
2020-12-31 6.914 -51.441 -75.868
2020-09-30 6.146 -49.779 -83.237
2020-06-30 7.684 -61.075 -146.75

ABUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABUS has a Quality Grade of D, ranking ahead of 23.96% of graded US stocks.
  • ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
  • ABBV, PLXP, and HSTO are the stocks whose asset turnover ratios are most correlated with ABUS.

The table below shows ABUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 1 -1.012
2021-03-31 0.059 1 -1.139
2020-12-31 0.059 1 -1.030
2020-09-30 0.056 1 -1.204
2020-06-30 0.073 1 -2.668
2020-03-31 0.053 1 -3.000

ABUS Price Target

For more insight on analysts targets of ABUS, see our ABUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 1.7 (Moderate Buy)

ABUS Stock Price Chart Interactive Chart >

Price chart for ABUS

ABUS Price/Volume Stats

Current price $3.07 52-week high $6.50
Prev. close $3.31 52-week low $2.43
Day low $3.06 Volume 3,385,400
Day high $3.31 Avg. volume 2,643,309
50-day MA $3.70 Dividend yield N/A
200-day MA $3.44 Market Cap 415.28M

Arbutus Biopharma Corporation (ABUS) Company Bio


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.


ABUS Latest News Stream


Event/Time News Detail
Loading, please wait...

ABUS Latest Social Stream


Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Yahoo | January 5, 2022

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtua

Yahoo | January 4, 2022

Arbutus Biopharma (NASDAQ:ABUS) Shares Down 2.9%

Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []

Transcript Daily | December 23, 2021

RNAi for Therapeutic Market 2021 Precise Outlook - Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

OpenPR | December 23, 2021

Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

Yahoo | December 23, 2021

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo -28.27%
3-mo -24.94%
6-mo 9.25%
1-year N/A
3-year -16.80%
5-year 20.39%
YTD -21.08%
2021 9.58%
2020 27.70%
2019 -27.42%
2018 -24.16%
2017 106.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0327 seconds.